jRCT2080220743未知3 期
DU-176b Phase III Clinical Study (Venous Thromboembolism) Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Hip Arthroplasty with Enoxaparin as an Active Control
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 600 人开始时间: 待定
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 600
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Double- blinded, parallel group controlled study
入排标准
- 年龄范围
- 20age old over 至 84age old under（—）
- 性别
- All
入选标准
- •Patients undergoing unilateral total hip arthroplasty
排除标准
- •Subjects with risks of hemorrhage
- •Subjects with thromboembolic risks
- •Subjects who weigh less than 40 kg
- •Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant
结局指标
主要结局
-
Proportion of subjects with venous thromboembolism events
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
DU-176b Phase III Clinical Study (Venous Thromboembolism) Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Hip Arthroplasty with Enoxaparin as an Active ControlJPRN-jRCT2080220743DAIICHISANKYO Co.,Ltd.600
未知
3 期
DU-176b Phase III Clinical Study (Venous Thromboembolism) -A multicenter, Randomized, Unblinded Study of DU-176b in Patients Undergoing Hip Fracture Surgery with Enoxaparin as a referencePatients undergoing hip fracture surgeryJPRN-jRCT2080220770DAIICHISANKYO Co.,Ltd.90
未知
3 期
DU-176b Phase III Clinical Study (Venous Thromboembolism) -A multicenter, Randomized, Unblinded Study of DU-176b in Patients Undergoing Hip Fracture Surgery with Enoxaparin as a reference -jRCT2080220770DAIICHISANKYO Co.,Ltd.90
未知
3 期
DU-176b Phase 3 Clinical Study (Venous Thromboembolism) -Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Knee Arthroplasty with Enoxaparin as an Active ControlJPRN-jRCT2080220701DAIICHISANKYO Co.,Ltd.520
未知
2 期
DU-176b Phase IIb clinical study (venous thromboembolism): Japan-Taiwan multicenter randomized double-blind dose-finding study using Enoxaparin as a reference in patients undergoing total hip replacementjRCT2080220798DAIICHISANKYO Co.,Ltd.210